APO Research
Talk to an analyst

APO RESEARCH · REPORT

Klebsiella Pneumoniae Infection Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Klebsiella Pneumoniae Infection Drug Market Analysis and Forecast 2026-2032

22 December 2025201 pages

Choose your research edition.

Industry ResearchKlebsiella Pneumoniae Infection Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Klebsiella Pneumoniae Infection Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Klebsiella Pneumoniae Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Klebsiella Pneumoniae Infection Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Klebsiella Pneumoniae Infection Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Klebsiella Pneumoniae Infection Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Klebsiella Pneumoniae Infection Drug include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and Melinta Therapeutics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Klebsiella Pneumoniae Infection Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Klebsiella Pneumoniae Infection Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Klebsiella Pneumoniae Infection Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Klebsiella Pneumoniae Infection Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Klebsiella Pneumoniae Infection Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Klebsiella Pneumoniae Infection Drug sales, projected growth trends, production technology, application and end-user industry.

Klebsiella Pneumoniae Infection Drug Segment by Company

Acies Bio doo

Appili Therapeutics

Debiopharm International SA

Evaxion Biotech ApS

FOB Synthesis Inc

ImmunoClin Corp

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Pfizer Inc

F. Hoffmann-La Roche Ltd

Klebsiella Pneumoniae Infection Drug Segment by Type

ATI-1503

CA-824

CC-1807

Cefiderocol

Debio-1454

EBX-004

Others

Klebsiella Pneumoniae Infection Drug Segment by Application

Hospital

Clinic

Others

Klebsiella Pneumoniae Infection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Klebsiella Pneumoniae Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Klebsiella Pneumoniae Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Klebsiella Pneumoniae Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Klebsiella Pneumoniae Infection Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Klebsiella Pneumoniae Infection Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Klebsiella Pneumoniae Infection Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. ATI-1503 Major Manufacturers Table 3. CA-824 Major Manufacturers Table 4. CC-1807 Major Manufacturers Table 5. Cefiderocol Major Manufacturers Table 6. Debio-1454 Major Manufacturers Table 7. EBX-004 Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Hospital Major Manufacturers Table 11. Clinic Major Manufacturers Table 12. Others Major Manufacturers Table 13. Klebsiella Pneumoniae Infection Drug Industry Trends Table 14. Klebsiella Pneumoniae Infection Drug Industry Drivers Table 15. Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges Table 16. Klebsiella Pneumoniae Infection Drug Industry Restraints Table 17. Global Klebsiella Pneumoniae Infection Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2021-2026) Table 21. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2027-2032) Table 22. Global Klebsiella Pneumoniae Infection Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 23. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026) & (k units) Table 24. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2027-2032) & (k units) Table 25. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2021-2026) Table 26. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2027-2032) Table 27. Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Klebsiella Pneumoniae Infection Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Manufacturers (2021-2026) Table 31. Global Klebsiella Pneumoniae Infection Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 32. Global Klebsiella Pneumoniae Infection Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Klebsiella Pneumoniae Infection Drug Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Klebsiella Pneumoniae Infection Drug Manufacturers, Product Type & Application Table 35. Global Klebsiella Pneumoniae Infection Drug Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Klebsiella Pneumoniae Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Klebsiella Pneumoniae Infection Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2026) Table 42. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2027-2032) Table 43. Global Klebsiella Pneumoniae Infection Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 44. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 45. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 46. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2026) Table 47. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2027-2032) Table 48. Global Klebsiella Pneumoniae Infection Drug Price by Type (2021-2026) & (US$/unit) Table 49. Global Klebsiella Pneumoniae Infection Drug Price by Type (2027-2032) & (US$/unit) Table 50. Global Klebsiella Pneumoniae Infection Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2026) Table 54. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2027-2032) Table 55. Global Klebsiella Pneumoniae Infection Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 56. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 57. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 58. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2026) Table 59. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2027-2032) Table 60. Global Klebsiella Pneumoniae Infection Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Klebsiella Pneumoniae Infection Drug Price by Application (2027-2032) & (US$/unit) Table 62. Acies Bio doo Company Information Table 63. Acies Bio doo Business Overview Table 64. Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio Table 66. Acies Bio doo Recent Development Table 67. Appili Therapeutics Company Information Table 68. Appili Therapeutics Business Overview Table 69. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio Table 71. Appili Therapeutics Recent Development Table 72. Debiopharm International SA Company Information Table 73. Debiopharm International SA Business Overview Table 74. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio Table 76. Debiopharm International SA Recent Development Table 77. Evaxion Biotech ApS Company Information Table 78. Evaxion Biotech ApS Business Overview Table 79. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 81. Evaxion Biotech ApS Recent Development Table 82. FOB Synthesis Inc Company Information Table 83. FOB Synthesis Inc Business Overview Table 84. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 86. FOB Synthesis Inc Recent Development Table 87. ImmunoClin Corp Company Information Table 88. ImmunoClin Corp Business Overview Table 89. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio Table 91. ImmunoClin Corp Recent Development Table 92. Innovation Pharmaceuticals Inc Company Information Table 93. Innovation Pharmaceuticals Inc Business Overview Table 94. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 96. Innovation Pharmaceuticals Inc Recent Development Table 97. Kyorin Pharmaceutical Co Ltd Company Information Table 98. Kyorin Pharmaceutical Co Ltd Business Overview Table 99. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 101. Kyorin Pharmaceutical Co Ltd Recent Development Table 102. Melinta Therapeutics Inc Company Information Table 103. Melinta Therapeutics Inc Business Overview Table 104. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 106. Melinta Therapeutics Inc Recent Development Table 107. Nosopharm SAS Company Information Table 108. Nosopharm SAS Business Overview Table 109. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 111. Nosopharm SAS Recent Development Table 112. Peptilogics Inc Company Information Table 113. Peptilogics Inc Business Overview Table 114. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 116. Peptilogics Inc Recent Development Table 117. Phico Therapeutics Ltd Company Information Table 118. Phico Therapeutics Ltd Business Overview Table 119. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 121. Phico Therapeutics Ltd Recent Development Table 122. Sarepta Therapeutics Inc Company Information Table 123. Sarepta Therapeutics Inc Business Overview Table 124. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 126. Sarepta Therapeutics Inc Recent Development Table 127. Shionogi & Co Ltd Company Information Table 128. Shionogi & Co Ltd Business Overview Table 129. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 131. Shionogi & Co Ltd Recent Development Table 132. Syntiron LLC Company Information Table 133. Syntiron LLC Business Overview Table 134. Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio Table 136. Syntiron LLC Recent Development Table 137. Tetraphase Pharmaceuticals Inc Company Information Table 138. Tetraphase Pharmaceuticals Inc Business Overview Table 139. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 141. Tetraphase Pharmaceuticals Inc Recent Development Table 142. Pfizer Inc Company Information Table 143. Pfizer Inc Business Overview Table 144. Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 145. Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 146. Pfizer Inc Recent Development Table 147. F. Hoffmann-La Roche Ltd Company Information Table 148. F. Hoffmann-La Roche Ltd Business Overview Table 149. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 150. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 151. F. Hoffmann-La Roche Ltd Recent Development Table 152. North America Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 153. North America Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 154. North America Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 155. North America Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 156. North America Klebsiella Pneumoniae Infection Drug Sales Price by Type (2021-2026) & (US$/unit) Table 157. North America Klebsiella Pneumoniae Infection Drug Sales Price by Type (2027-2032) & (US$/unit) Table 158. North America Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 159. North America Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 160. North America Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 161. North America Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 162. North America Klebsiella Pneumoniae Infection Drug Sales Price by Application (2021-2026) & (US$/unit) Table 163. North America Klebsiella Pneumoniae Infection Drug Sales Price by Application (2027-2032) & (US$/unit) Table 164. North America Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. North America Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 166. North America Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 167. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 168. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 169. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 170. North America Klebsiella Pneumoniae Infection Drug Sales Price by Country (2021-2026) & (US$/unit) Table 171. North America Klebsiella Pneumoniae Infection Drug Sales Price by Country (2027-2032) & (US$/unit) Table 172. United States Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 173. Canada Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 174. Mexico Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 175. Europe Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 176. Europe Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 177. Europe Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 178. Europe Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 179. Europe Klebsiella Pneumoniae Infection Drug Sales Price by Type (2021-2026) & (US$/unit) Table 180. Europe Klebsiella Pneumoniae Infection Drug Sales Price by Type (2027-2032) & (US$/unit) Table 181. Europe Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 182. Europe Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 183. Europe Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 184. Europe Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 185. Europe Klebsiella Pneumoniae Infection Drug Sales Price by Application (2021-2026) & (US$/unit) Table 186. Europe Klebsiella Pneumoniae Infection Drug Sales Price by Application (2027-2032) & (US$/unit) Table 187. Europe Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 188. Europe Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 189. Europe Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 190. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 191. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 192. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 193. Europe Klebsiella Pneumoniae Infection Drug Sales Price by Country (2021-2026) & (US$/unit) Table 194. Europe Klebsiella Pneumoniae Infection Drug Sales Price by Country (2027-2032) & (US$/unit) Table 195. Germany Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 196. France Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 197. U.K. Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 198. Italy Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 199. Russia Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 200. Spain Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 201. Netherlands Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 202. Switzerland Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 203. Sweden Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 204. Poland Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 205. China Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 206. China Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 207. China Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 208. China Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 209. China Klebsiella Pneumoniae Infection Drug Sales Price by Type (2021-2026) & (US$/unit) Table 210. China Klebsiella Pneumoniae Infection Drug Sales Price by Type (2027-2032) & (US$/unit) Table 211. China Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 212. China Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 213. China Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 214. China Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 215. China Klebsiella Pneumoniae Infection Drug Sales Price by Application (2021-2026) & (US$/unit) Table 216. China Klebsiella Pneumoniae Infection Drug Sales Price by Application (2027-2032) & (US$/unit) Table 217. Asia Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 218. Asia Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 219. Asia Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 220. Asia Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 221. Asia Klebsiella Pneumoniae Infection Drug Sales Price by Type (2021-2026) & (US$/unit) Table 222. Asia Klebsiella Pneumoniae Infection Drug Sales Price by Type (2027-2032) & (US$/unit) Table 223. Asia Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 224. Asia Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 225. Asia Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 226. Asia Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 227. Asia Klebsiella Pneumoniae Infection Drug Sales Price by Application (2021-2026) & (US$/unit) Table 228. Asia Klebsiella Pneumoniae Infection Drug Sales Price by Application (2027-2032) & (US$/unit) Table 229. Asia Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 230. Asia Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 231. Asia Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 232. Asia Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 233. Asia Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 234. Asia Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 235. Asia Klebsiella Pneumoniae Infection Drug Sales Price by Country (2021-2026) & (US$/unit) Table 236. Asia Klebsiella Pneumoniae Infection Drug Sales Price by Country (2027-2032) & (US$/unit) Table 237. Japan Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 238. South Korea Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 239. India Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 240. Australia Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 241. Taiwan Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 242. Southeast Asia Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 243. SAMEA Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 244. SAMEA Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 245. SAMEA Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 246. SAMEA Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 247. SAMEA Klebsiella Pneumoniae Infection Drug Sales Price by Type (2021-2026) & (US$/unit) Table 248. SAMEA Klebsiella Pneumoniae Infection Drug Sales Price by Type (2027-2032) & (US$/unit) Table 249. SAMEA Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 250. SAMEA Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 251. SAMEA Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 252. SAMEA Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 253. SAMEA Klebsiella Pneumoniae Infection Drug Sales Price by Application (2021-2026) & (US$/unit) Table 254. SAMEA Klebsiella Pneumoniae Infection Drug Sales Price by Application (2027-2032) & (US$/unit) Table 255. SAMEA Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 256. SAMEA Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 257. SAMEA Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 258. SAMEA Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 259. SAMEA Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 260. SAMEA Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 261. SAMEA Klebsiella Pneumoniae Infection Drug Sales Price by Country (2021-2026) & (US$/unit) Table 262. SAMEA Klebsiella Pneumoniae Infection Drug Sales Price by Country (2027-2032) & (US$/unit) Table 263. Brazil Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 264. Argentina Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 265. Chile Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 266. Colombia Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 267. Peru Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 268. Saudi Arabia Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 269. Israel Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 270. UAE Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 271. Turkey Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 272. Iran Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 273. Egypt Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Table 274. Key Raw Materials Table 275. Raw Materials Key Suppliers Table 276. Klebsiella Pneumoniae Infection Drug Distributors List Table 277. Klebsiella Pneumoniae Infection Drug Customers List Table 278. Research Programs/Design for This Report Table 279. Authors List of This Report Table 280. Secondary Sources Table 281. Primary Sources List of Figures Figure 1. Klebsiella Pneumoniae Infection Drug Image Figure 2. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Klebsiella Pneumoniae Infection Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. ATI-1503 Image Figure 5. CA-824 Image Figure 6. CC-1807 Image Figure 7. Cefiderocol Image Figure 8. Debio-1454 Image Figure 9. EBX-004 Image Figure 10. Others Image Figure 11. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Klebsiella Pneumoniae Infection Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Others Image Figure 16. Global Klebsiella Pneumoniae Infection Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Klebsiella Pneumoniae Infection Drug Revenue (2021-2032) & (US$ Million) Figure 18. Global Klebsiella Pneumoniae Infection Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2021-2032) Figure 21. Global Klebsiella Pneumoniae Infection Drug Sales (2021-2032) & (k units) Figure 22. Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 23. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Klebsiella Pneumoniae Infection Drug Sales YoY (2021-2032) & (k units) Figure 25. Europe Klebsiella Pneumoniae Infection Drug Sales YoY (2021-2032) & (k units) Figure 26. China Klebsiella Pneumoniae Infection Drug Sales YoY (2021-2032) & (k units) Figure 27. Asia (Excluding China) Klebsiella Pneumoniae Infection Drug Sales YoY (2021-2032) & (k units) Figure 28. South America, Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales YoY (2021-2032) & (k units) Figure 29. Global Klebsiella Pneumoniae Infection Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Klebsiella Pneumoniae Infection Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2032) Figure 35. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2032) Figure 38. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2032) Figure 41. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 42. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2032) Figure 44. North America Klebsiella Pneumoniae Infection Drug Revenue Share by Type (2021-2032) Figure 45. North America Klebsiella Pneumoniae Infection Drug Sales Share by Type (2021-2032) Figure 46. North America Klebsiella Pneumoniae Infection Drug Revenue Share by Application (2021-2032) Figure 47. North America Klebsiella Pneumoniae Infection Drug Sales Share by Application (2021-2032) Figure 48. North America Klebsiella Pneumoniae Infection Drug Revenue Share by Country (2021-2032) Figure 49. North America Klebsiella Pneumoniae Infection Drug Sales Share by Country (2021-2032) Figure 50. Europe Klebsiella Pneumoniae Infection Drug Revenue Share by Type (2021-2032) Figure 51. Europe Klebsiella Pneumoniae Infection Drug Sales Share by Type (2021-2032) Figure 52. Europe Klebsiella Pneumoniae Infection Drug Revenue Share by Application (2021-2032) Figure 53. Europe Klebsiella Pneumoniae Infection Drug Sales Share by Application (2021-2032) Figure 54. Europe Klebsiella Pneumoniae Infection Drug Revenue Share by Country (2021-2032) Figure 55. Europe Klebsiella Pneumoniae Infection Drug Sales Share by Country (2021-2032) Figure 56. China Klebsiella Pneumoniae Infection Drug Revenue Share by Type (2021-2032) Figure 57. China Klebsiella Pneumoniae Infection Drug Sales Share by Type (2021-2032) Figure 58. China Klebsiella Pneumoniae Infection Drug Revenue Share by Application (2021-2032) Figure 59. China Klebsiella Pneumoniae Infection Drug Sales Share by Application (2021-2032) Figure 60. Asia Klebsiella Pneumoniae Infection Drug Revenue Share by Type (2021-2032) Figure 61. Asia Klebsiella Pneumoniae Infection Drug Sales Share by Type (2021-2032) Figure 62. Asia Klebsiella Pneumoniae Infection Drug Revenue Share by Application (2021-2032) Figure 63. Asia Klebsiella Pneumoniae Infection Drug Sales Share by Application (2021-2032) Figure 64. Asia Klebsiella Pneumoniae Infection Drug Revenue Share by Country (2021-2032) Figure 65. Asia Klebsiella Pneumoniae Infection Drug Sales Share by Country (2021-2032) Figure 66. SAMEA Klebsiella Pneumoniae Infection Drug Revenue Share by Type (2021-2032) Figure 67. SAMEA Klebsiella Pneumoniae Infection Drug Sales Share by Type (2021-2032) Figure 68. SAMEA Klebsiella Pneumoniae Infection Drug Rev

Scope & coverage.

Types
  • ATI-1503
  • CA-824
  • CC-1807
  • Cefiderocol
  • Debio-1454
  • EBX-004
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Acies Bio doo
  • Appili Therapeutics
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • Innovation Pharmaceuticals Inc
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Klebsiella Pneumoniae Infection Drug Market by Type
  3. 1.2.1 Global Klebsiella Pneumoniae Infection Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 ATI-1503
  5. 1.2.3 CA-824
  6. 1.2.4 CC-1807
  7. 1.2.5 Cefiderocol
  8. 1.2.6 Debio-1454
  9. 1.2.7 EBX-004
  10. 1.2.8 Others
  11. 1.3 Klebsiella Pneumoniae Infection Drug Market by Application
  12. 1.3.1 Global Klebsiella Pneumoniae Infection Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Hospital
  14. 1.3.3 Clinic
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Klebsiella Pneumoniae Infection Drug Market Dynamics
  1. 2.1 Klebsiella Pneumoniae Infection Drug Industry Trends
  2. 2.2 Klebsiella Pneumoniae Infection Drug Industry Drivers
  3. 2.3 Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges
  4. 2.4 Klebsiella Pneumoniae Infection Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Klebsiella Pneumoniae Infection Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Region
  3. 3.2.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Klebsiella Pneumoniae Infection Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Klebsiella Pneumoniae Infection Drug Sales by Region
  9. 3.4.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers
  2. 4.1.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Klebsiella Pneumoniae Infection Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Klebsiella Pneumoniae Infection Drug Sales by Manufacturers
  6. 4.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Klebsiella Pneumoniae Infection Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Klebsiella Pneumoniae Infection Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Klebsiella Pneumoniae Infection Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Klebsiella Pneumoniae Infection Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Klebsiella Pneumoniae Infection Drug Manufacturers, Product Type & Application
  13. 4.7 Global Klebsiella Pneumoniae Infection Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Klebsiella Pneumoniae Infection Drug Market CR5 and HHI
  16. 4.8.2 2025 Klebsiella Pneumoniae Infection Drug Tier 1, Tier 2, and Tier 3
5 Klebsiella Pneumoniae Infection Drug Market by Type
  1. 5.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Type
  2. 5.1.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Klebsiella Pneumoniae Infection Drug Sales by Type
  6. 5.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Klebsiella Pneumoniae Infection Drug Price by Type
6 Klebsiella Pneumoniae Infection Drug Market by Application
  1. 6.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Application
  2. 6.1.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Klebsiella Pneumoniae Infection Drug Sales by Application
  6. 6.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Klebsiella Pneumoniae Infection Drug Price by Application
7 Company Profiles
  1. 7.1 Acies Bio doo
  2. 7.1.1 Acies Bio doo Company Information
  3. 7.1.2 Acies Bio doo Business Overview
  4. 7.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio
  6. 7.1.5 Acies Bio doo Recent Developments
  7. 7.2 Appili Therapeutics
  8. 7.2.1 Appili Therapeutics Company Information
  9. 7.2.2 Appili Therapeutics Business Overview
  10. 7.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio
  12. 7.2.5 Appili Therapeutics Recent Developments
  13. 7.3 Debiopharm International SA
  14. 7.3.1 Debiopharm International SA Company Information
  15. 7.3.2 Debiopharm International SA Business Overview
  16. 7.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio
  18. 7.3.5 Debiopharm International SA Recent Developments
  19. 7.4 Evaxion Biotech ApS
  20. 7.4.1 Evaxion Biotech ApS Company Information
  21. 7.4.2 Evaxion Biotech ApS Business Overview
  22. 7.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio
  24. 7.4.5 Evaxion Biotech ApS Recent Developments
  25. 7.5 FOB Synthesis Inc
  26. 7.5.1 FOB Synthesis Inc Company Information
  27. 7.5.2 FOB Synthesis Inc Business Overview
  28. 7.5.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  30. 7.5.5 FOB Synthesis Inc Recent Developments
  31. 7.6 ImmunoClin Corp
  32. 7.6.1 ImmunoClin Corp Company Information
  33. 7.6.2 ImmunoClin Corp Business Overview
  34. 7.6.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio
  36. 7.6.5 ImmunoClin Corp Recent Developments
  37. 7.7 Innovation Pharmaceuticals Inc
  38. 7.7.1 Innovation Pharmaceuticals Inc Company Information
  39. 7.7.2 Innovation Pharmaceuticals Inc Business Overview
  40. 7.7.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  42. 7.7.5 Innovation Pharmaceuticals Inc Recent Developments
  43. 7.8 Kyorin Pharmaceutical Co Ltd
  44. 7.8.1 Kyorin Pharmaceutical Co Ltd Company Information
  45. 7.8.2 Kyorin Pharmaceutical Co Ltd Business Overview
  46. 7.8.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  48. 7.8.5 Kyorin Pharmaceutical Co Ltd Recent Developments
  49. 7.9 Melinta Therapeutics Inc
  50. 7.9.1 Melinta Therapeutics Inc Company Information
  51. 7.9.2 Melinta Therapeutics Inc Business Overview
  52. 7.9.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  54. 7.9.5 Melinta Therapeutics Inc Recent Developments
  55. 7.10 Nosopharm SAS
  56. 7.10.1 Nosopharm SAS Company Information
  57. 7.10.2 Nosopharm SAS Business Overview
  58. 7.10.3 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio
  60. 7.10.5 Nosopharm SAS Recent Developments
  61. 7.11 Peptilogics Inc
  62. 7.11.1 Peptilogics Inc Company Information
  63. 7.11.2 Peptilogics Inc Business Overview
  64. 7.11.3 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  66. 7.11.5 Peptilogics Inc Recent Developments
  67. 7.12 Phico Therapeutics Ltd
  68. 7.12.1 Phico Therapeutics Ltd Company Information
  69. 7.12.2 Phico Therapeutics Ltd Business Overview
  70. 7.12.3 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  72. 7.12.5 Phico Therapeutics Ltd Recent Developments
  73. 7.13 Sarepta Therapeutics Inc
  74. 7.13.1 Sarepta Therapeutics Inc Company Information
  75. 7.13.2 Sarepta Therapeutics Inc Business Overview
  76. 7.13.3 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  78. 7.13.5 Sarepta Therapeutics Inc Recent Developments
  79. 7.14 Shionogi & Co Ltd
  80. 7.14.1 Shionogi & Co Ltd Company Information
  81. 7.14.2 Shionogi & Co Ltd Business Overview
  82. 7.14.3 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  84. 7.14.5 Shionogi & Co Ltd Recent Developments
  85. 7.15 Syntiron LLC
  86. 7.15.1 Syntiron LLC Company Information
  87. 7.15.2 Syntiron LLC Business Overview
  88. 7.15.3 Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio
  90. 7.15.5 Syntiron LLC Recent Developments
  91. 7.16 Tetraphase Pharmaceuticals Inc
  92. 7.16.1 Tetraphase Pharmaceuticals Inc Company Information
  93. 7.16.2 Tetraphase Pharmaceuticals Inc Business Overview
  94. 7.16.3 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  96. 7.16.5 Tetraphase Pharmaceuticals Inc Recent Developments
  97. 7.17 Pfizer Inc
  98. 7.17.1 Pfizer Inc Company Information
  99. 7.17.2 Pfizer Inc Business Overview
  100. 7.17.3 Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  102. 7.17.5 Pfizer Inc Recent Developments
  103. 7.18 F. Hoffmann-La Roche Ltd
  104. 7.18.1 F. Hoffmann-La Roche Ltd Company Information
  105. 7.18.2 F. Hoffmann-La Roche Ltd Business Overview
  106. 7.18.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  108. 7.18.5 F. Hoffmann-La Roche Ltd Recent Developments
8 North America
  1. 8.1 North America Klebsiella Pneumoniae Infection Drug Market Size by Type
  2. 8.1.1 North America Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Klebsiella Pneumoniae Infection Drug Price by Type (2021-2032)
  5. 8.2 North America Klebsiella Pneumoniae Infection Drug Market Size by Application
  6. 8.2.1 North America Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Klebsiella Pneumoniae Infection Drug Price by Application (2021-2032)
  9. 8.3 North America Klebsiella Pneumoniae Infection Drug Market Size by Country
  10. 8.3.1 North America Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Klebsiella Pneumoniae Infection Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Klebsiella Pneumoniae Infection Drug Market Size by Type
  2. 9.1.1 Europe Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Klebsiella Pneumoniae Infection Drug Price by Type (2021-2032)
  5. 9.2 Europe Klebsiella Pneumoniae Infection Drug Market Size by Application
  6. 9.2.1 Europe Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Klebsiella Pneumoniae Infection Drug Price by Application (2021-2032)
  9. 9.3 Europe Klebsiella Pneumoniae Infection Drug Market Size by Country
  10. 9.3.1 Europe Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Klebsiella Pneumoniae Infection Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Klebsiella Pneumoniae Infection Drug Market Size by Type
  2. 10.1.1 China Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032)
  4. 10.1.3 China Klebsiella Pneumoniae Infection Drug Price by Type (2021-2032)
  5. 10.2 China Klebsiella Pneumoniae Infection Drug Market Size by Application
  6. 10.2.1 China Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032)
  8. 10.2.3 China Klebsiella Pneumoniae Infection Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Klebsiella Pneumoniae Infection Drug Market Size by Type
  2. 11.1.1 Asia Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Klebsiella Pneumoniae Infection Drug Price by Type (2021-2032)
  5. 11.2 Asia Klebsiella Pneumoniae Infection Drug Market Size by Application
  6. 11.2.1 Asia Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Klebsiella Pneumoniae Infection Drug Price by Application (2021-2032)
  9. 11.3 Asia Klebsiella Pneumoniae Infection Drug Market Size by Country
  10. 11.3.1 Asia Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Klebsiella Pneumoniae Infection Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Klebsiella Pneumoniae Infection Drug Market Size by Type
  2. 12.1.1 SAMEA Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Klebsiella Pneumoniae Infection Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Klebsiella Pneumoniae Infection Drug Market Size by Application
  6. 12.2.1 SAMEA Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Klebsiella Pneumoniae Infection Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Klebsiella Pneumoniae Infection Drug Market Size by Country
  10. 12.3.1 SAMEA Klebsiella Pneumoniae Infection Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Klebsiella Pneumoniae Infection Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Klebsiella Pneumoniae Infection Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Klebsiella Pneumoniae Infection Drug Value Chain Analysis
  2. 13.1.1 Klebsiella Pneumoniae Infection Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Klebsiella Pneumoniae Infection Drug Production Mode & Process
  6. 13.2 Klebsiella Pneumoniae Infection Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Klebsiella Pneumoniae Infection Drug Distributors
  9. 13.2.3 Klebsiella Pneumoniae Infection Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst